BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 12740905)

  • 1. Carboplatin induces Fas (APO-1/CD95)-dependent apoptosis of human tongue carcinoma cells: sensitization for apoptosis by upregulation of FADD expression.
    Mishima K; Nariai Y; Yoshimura Y
    Int J Cancer; 2003 Jul; 105(5):593-600. PubMed ID: 12740905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fas ligand-independent, FADD-mediated activation of the Fas death pathway by anticancer drugs.
    Micheau O; Solary E; Hammann A; Dimanche-Boitrel MT
    J Biol Chem; 1999 Mar; 274(12):7987-92. PubMed ID: 10075697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential involvement of the CD95 (Fas/APO-1) receptor/ligand system on apoptosis induced by the wild-type p53 gene transfer in human cancer cells.
    Fukazawa T; Fujiwara T; Morimoto Y; Shao J; Nishizaki M; Kadowaki Y; Hizuta A; Owen-Schaub LB; Roth JA; Tanaka N
    Oncogene; 1999 Apr; 18(13):2189-99. PubMed ID: 10327065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Up-regulation of Fas (APO-1/CD95) ligand and down-regulation of Fas expression in human esophageal cancer.
    Gratas C; Tohma Y; Barnas C; Taniere P; Hainaut P; Ohgaki H
    Cancer Res; 1998 May; 58(10):2057-62. PubMed ID: 9605741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human pancreatic adenocarcinomas express Fas and Fas ligand yet are resistant to Fas-mediated apoptosis.
    Ungefroren H; Voss M; Jansen M; Roeder C; Henne-Bruns D; Kremer B; Kalthoff H
    Cancer Res; 1998 Apr; 58(8):1741-9. PubMed ID: 9563493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug-induced apoptosis is associated with enhanced Fas (Apo-1/CD95) ligand expression but occurs independently of Fas (Apo-1/CD95) signaling in human T-acute lymphatic leukemia cells.
    Villunger A; Egle A; Kos M; Hartmann BL; Geley S; Kofler R; Greil R
    Cancer Res; 1997 Aug; 57(16):3331-4. PubMed ID: 9269989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. On the role and significance of Fas (Apo-1/CD95) ligand (FasL) expression in immune privileged tissues and cancer cells using multiple myeloma as a model.
    Greil R; Egle A; Villunger A
    Leuk Lymphoma; 1998 Nov; 31(5-6):477-90. PubMed ID: 9922038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sensitization of human bladder cancer cells to Fas-mediated cytotoxicity by cis-diamminedichloroplatinum (II).
    Mizutani Y; Yoshida O; Bonavida B
    J Urol; 1998 Aug; 160(2):561-70. PubMed ID: 9679929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53.
    Müller M; Strand S; Hug H; Heinemann EM; Walczak H; Hofmann WJ; Stremmel W; Krammer PH; Galle PR
    J Clin Invest; 1997 Feb; 99(3):403-13. PubMed ID: 9022073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation and activation-induced death of human tonsillar B cells and Burkitt lymphoma cells: lack of CD95 (Fas/APO-1) ligand expression and function.
    Daniel PT; Oettinger U; Mapara MY; Bommert K; Bargou R; Dörken B
    Eur J Immunol; 1997 Apr; 27(4):1029-34. PubMed ID: 9130660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-Fas antibody differentially regulates apoptosis in Fas ligand resistant carcinoma lines via the caspase 3 family of cell death proteases but independently of bcl2 expression.
    Crowe DL; Boardman ML; Fong KS
    Anticancer Res; 1998; 18(5A):3163-70. PubMed ID: 9858879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suppression of human B cell responsiveness by CD4+ T cells does not involve CD95-CD95 ligand interactions.
    Hirohata S
    Cell Immunol; 1997 Nov; 181(2):182-91. PubMed ID: 9398405
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Involvement of Fas ligand and Fas-mediated pathway in the cytotoxicity of human natural killer cells.
    Oshimi Y; Oda S; Honda Y; Nagata S; Miyazaki S
    J Immunol; 1996 Oct; 157(7):2909-15. PubMed ID: 8816396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms of apoptosis in T cells from patients with renal cell carcinoma.
    Uzzo RG; Rayman P; Kolenko V; Clark PE; Bloom T; Ward AM; Molto L; Tannenbaum C; Worford LJ; Bukowski R; Tubbs R; Hsi ED; Bander NH; Novick AC; Finke JH
    Clin Cancer Res; 1999 May; 5(5):1219-29. PubMed ID: 10353760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ultraviolet light induces apoptosis via direct activation of CD95 (Fas/APO-1) independently of its ligand CD95L.
    Aragane Y; Kulms D; Metze D; Wilkes G; Pöppelmann B; Luger TA; Schwarz T
    J Cell Biol; 1998 Jan; 140(1):171-82. PubMed ID: 9425165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fas ligand is constitutively secreted by prostate cancer cells in vitro.
    Liu QY; Rubin MA; Omene C; Lederman S; Stein CA
    Clin Cancer Res; 1998 Jul; 4(7):1803-11. PubMed ID: 9676859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Local Fas/APO-1 (CD95) ligand-mediated tumor cell killing in vivo.
    Rensing-Ehl A; Frei K; Flury R; Matiba B; Mariani SM; Weller M; Aebischer P; Krammer PH; Fontana A
    Eur J Immunol; 1995 Aug; 25(8):2253-8. PubMed ID: 7545115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human lung carcinomas express Fas ligand.
    Niehans GA; Brunner T; Frizelle SP; Liston JC; Salerno CT; Knapp DJ; Green DR; Kratzke RA
    Cancer Res; 1997 Mar; 57(6):1007-12. PubMed ID: 9067260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apoptosis in human hepatoma cell lines by chemotherapeutic drugs via Fas-dependent and Fas-independent pathways.
    Jiang S; Song MJ; Shin EC; Lee MO; Kim SJ; Park JH
    Hepatology; 1999 Jan; 29(1):101-10. PubMed ID: 9862856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FADD gene therapy for malignant gliomas in vitro and in vivo.
    Kondo S; Ishizaka Y; Okada T; Kondo Y; Hitomi M; Tanaka Y; Haqqi T; Barnett GH; Barna BP
    Hum Gene Ther; 1998 Jul; 9(11):1599-608. PubMed ID: 9694158
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.